Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands

被引:185
作者
Horowitz, MC [1 ]
Xi, YG [1 ]
Wilson, K [1 ]
Kacena, MA [1 ]
机构
[1] Yale Univ, Sch Med, Dept Orthopaed & Rehabil, New Haven, CT 06510 USA
关键词
osteoclastogenesis; osteoblasts; bone resorption;
D O I
10.1016/S1359-6101(00)00030-7
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Skeletal mass is maintained by a balance between cells which resorb bone (osteoclasts) and cells which form bone (osteoblasts). Bone development and growth is an on-going. life-long process. Bone is formed during embryonic lift, grow's rapidly through childhood, and peaks around 20 years of age (formation exceeds resorption). For humans the skeleton then enters a long period, approximately 40 years, when bone mass remains relatively stable. Skeletal turnover continues but the net effect of resorption and formation on bone mass is zero. For women this ends when they enter menopause and similar bone loss occurs for men. but later in life. These opposite functions: are coupled, resorption precedes formation. and osteoblasts, or their precursors, stromal cells. regulate osteoclast formation and activity. Until recently, the molecular nature of this regulation, was pool ly understood. However, recent observations have identified members of the TNF family of ligands and receptors as critical regulators of osteoclastogenesis. Osteoprotegerin (OPG) a decoy receptor was first identified. Its ligand, receptor activator of nuclear factor-kappaB ligand (RANKL), was quickly found, and shown to be expressed on stromal cells and osteoblasts. Its cognate receptor, RANK, was found to be expressed in high levels on osteoclast precursors. The interaction between RANKL and RANK was shown to be required for osteoclast formation. These observations have provided a molecular understanding of the coupling between osteoclastic bone resorption and osteoblastic bone formation. Moreover. they provide a framework on which to base a clear understanding of normal (e.g. postmenopausal osteoporosis and age associated bone loss) and pathologic skeletal changes (e.g. osteopetrosis. glucocorticoid-induced osteoporosis, periodontal disease, bone metastases. Paget's disease, hyperparathyroidism, and rheumatoid arthritis). (C) 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:9 / 18
页数:10
相关论文
共 74 条
  • [41] Lorenzo JA, 2000, J BONE MINER RES, V15, pS182
  • [42] Evidence for a role of a tumor necrosis factor-α (TNF-α)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival
    Lum, L
    Wong, BR
    Josien, R
    Becherer, JD
    Erdjument-Bromage, H
    Schlöndorff, J
    Tempst, P
    Choi, Y
    Blobel, CP
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (19) : 13613 - 13618
  • [43] Selective inhibition of NF-κB activation by a peptide that blocks the interaction of NEMO with the IκB kinase complex
    May, MJ
    D'Acquisto, F
    Madge, LA
    Glöckner, J
    Pober, JS
    Ghosh, S
    [J]. SCIENCE, 2000, 289 (5484) : 1550 - 1554
  • [44] Transforming growth factor-β1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells
    Murakami, T
    Yamamoto, M
    Yamamoto, M
    Ono, K
    Nishikawa, M
    Nagata, N
    Motoyoshi, K
    Akatsu, T
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 252 (03) : 747 - 752
  • [45] Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice
    Naito, A
    Azuma, S
    Tanaka, S
    Miyazaki, T
    Takaki, S
    Takatsu, K
    Nakao, K
    Nakamura, K
    Katsuki, M
    Yamamoto, T
    Inoue, J
    [J]. GENES TO CELLS, 1999, 4 (06) : 353 - 362
  • [46] RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis
    Nakagawa, N
    Kinosaki, M
    Yamaguchi, K
    Shima, N
    Yasuda, H
    Yano, K
    Morinaga, T
    Higashio, K
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 253 (02) : 395 - 400
  • [47] Nishii M, 1999, J BONE MINER RES, V14, pS483
  • [48] OBRIEN CA, 1998, BONE S1, V23, P1003
  • [49] An antagonist decoy receptor and a death domain-containing receptor for TRAIL
    Pan, GH
    Ni, J
    Wei, YF
    Yu, GL
    Gentz, R
    Dixit, VM
    [J]. SCIENCE, 1997, 277 (5327) : 815 - 818
  • [50] The receptor for the cytotoxic ligand TRAIL
    Pan, GH
    ORourke, K
    Chinnaiyan, AM
    Gentz, R
    Ebner, R
    Ni, J
    Dixit, VM
    [J]. SCIENCE, 1997, 276 (5309) : 111 - 113